Evidence map›Paper›PMID 30997054›Full record

ArticleClinical case reports2019

Nivolumab and immune-mediated colitis.

Heather Walker, Paul Brennan, Maximillian Groome, Shaun Walsh, Frank Carey

Open access · goldAbstract readCase Reports
In one paragraph

Article in Clinical case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Nivolumab and immune-mediated colitis.Clinical case reports · 2019
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Heather WalkerNinewells Hospital and Medical School, University of Dundee and NHS Tayside Dundee UK.ORCID https://orcid.org/0000-0003-0148-0766
Paul BrennanNinewells Hospital and Medical School, University of Dundee and NHS Tayside Dundee UK.ORCID https://orcid.org/0000-0001-8368-1478
Maximillian GroomeDepartment of Gastroenterology Ninewells Hospital and Medical School Dundee UK.
Shaun WalshDepartment of Pathology Ninewells Hospital and Medical School Dundee UK.
Frank CareyDepartment of Pathology Ninewells Hospital and Medical School Dundee UK.
Ninewells Hospital · GBUniversity of Dundee · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nivolumab is associated with a number of immune-regulated adverse events, including immune-mediated colitis and may present following the discontinuation of treatment. Current guidance suggests lower doses of methylprednisolone; however, we described faster resolution of the patient's symptoms compared to previous reported cases, using higher dosing, thereby minimizing hospitalization.

Indexed as

immune‐mediated colitisimmune‐regulated adverse eventsNivolumabPD‐1 receptor

Identifiers

PMID30997054
PMCPMC6452469
OpenAlexW2917442687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.